Pfizer will have to pay rebates to Medicare for five drugs under Biden plan to lower Rx costs

Pfizer will have to pay rebates to Medicare for five drugs under Biden plan to lower Rx costs


President Joe Biden delivers remarks about the Build Back Better legislation’s new rules around prescription drug prices in the East Room of the White House on December 06, 2021 in Washington, DC.

Chip Somodevilla | Getty Images

Five of Pfizer’s drugs will cost less for Medicare recipients starting next month as part of President Joe Biden’s plan to lower prescription drug costs, the Department of Health and Human Services said Wednesday. 

Pfizer’s drugs are among the first set of 27 Part B prescription drugs that will be subject to Medicare inflation rebates starting April 1, according to the department. That requires Pfizer and other prescription drug companies to refund Medicare through rebates because the prices for those drugs rose faster than the rate of inflation. 

Pfizer’s drugs include the blood thinner Fragmin, which was approved by the Food and Drug Administration in 1994. It also includes Atgam, a medicine used to treat symptoms of Renal Allograft and Aplastic Anemia, and the chemotherapy injection Nipent. Pfizer’s antibacterial drugs Bicillin L-A, used for treating syphilis, and Bicillin C-R are also included. Both drugs are also used to treat upper respiratory infections.

Seniors could see their out-of-pocket costs for the drugs decrease by $2 to as much as $390 per average dose, the department said. The amount that Medicare beneficiaries will save depends on several factors, such as what their treatment protocol is and whether they have supplemental coverage. 

The savings stem from a provision of the Inflation Reduction Act, which congressional Democrats passed last August. The announcement is also part of Biden’s broader push to reduce healthcare costs for Americans amid stubbornly high inflation. 

In addition to the rebates, the provision discourages other companies from hiking their prices at a faster rate than inflation in the future, the department said. An HHS report released in September 2022 found that the prices of 1,200 prescription drugs increased faster than inflation in 2021, one year before the IRA was signed into law. 

Later this year, Medicare will start negotiating lower prescription drug prices for its beneficiaries. 

“Already, millions of seniors are saving hundreds of dollars each per year because of the Biden Administration’s actions, and President Biden is fighting to expand these cost savings to all Americans,” the White House said in a statement. 



Source

2026 will bring more GLP-1 weight loss pills — and new habits. These stocks are poised to benefit
Health

2026 will bring more GLP-1 weight loss pills — and new habits. These stocks are poised to benefit

The ripple is about to become a wave. Right now, there are numerous barriers for people who are considering treating their obesity with GLP-1 drugs. Early on, there were manufacturing bottlenecks that resulted in short supplies of Novo Nordisk ‘s Wegovy and Eli Lilly ‘s Zepbound. There were insurance coverage issues for these pricey treatments, […]

Read More
Eli Lilly investors shouldn’t sweat rival Novo Nordisk having the first obesity pill on sale
Health

Eli Lilly investors shouldn’t sweat rival Novo Nordisk having the first obesity pill on sale

Jim Cramer says don’t sweat Novo Nordisk’s head start over Club holding Eli Lilly in the obesity pill market. Eli Lilly stock slipped about half a percent this morning, while Novo Nordisk shares surged more than 8% after becoming the first to secure FDA approval for a GLP-1 weight-loss pill. “[Novo] got approval ahead of […]

Read More
FDA approves first GLP-1 pill for obesity from Wegovy maker Novo Nordisk
Health

FDA approves first GLP-1 pill for obesity from Wegovy maker Novo Nordisk

The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, on the outskirts of Copenhagen, Denmark, Nov. 24, 2025. Tom Little | Reuters The U.S. Food and Drug Administration on Monday approved the first-ever GLP-1 pill for obesity from Wegovy maker Novo Nordisk, a landmark decision that health experts […]

Read More